Table 3 Diagnosis criteria, characteristics and antifungal therapy of patients (n = 29) diagnosed with Coronavirus disease (COVID-19)-associated pulmonary aspergillosis (CAPA)
Variable | CAPA patients, n = 29 |
|---|---|
CAPA diagnosis criteria | |
CAPA proven/probable | 24 (83) |
CAPA possible | 5 (17) |
Time from ICU admission to CAPA diagnosis, days | 5 [2–16] |
Immunosuppression | 15 (52) |
Haematological malignancies | 10 (66) |
Solid organ transplantation | 4 (27) |
Immunosuppressive drugs | 1 (7) |
IMV | 22 (76) |
Time from IMV to CAPA diagnosis, days | 6 [2–13] |
Antifungal therapy | 28 (97) |
Azole antifungals | 28 (100) |
Voriconazole | 24 (86) |
Isavuconazole | 4 (14) |
Itraconazole | 1 (4) |
Posaconazole | 1 (4) |
Caspofungin | 2 (7) |
Liposomal amphotericin B | 2 (7) |